---
document_datetime: 2023-09-21 18:41:19
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/toviaz-epar-all-authorised-presentations_en.pdf
document_name: toviaz-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 2.1300467
conversion_datetime: 2025-12-23 06:08:29.688817
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) Number   | (Invented) name   | Strength   | Pharmaceutical Form      | Route of Administration   | Immediate Packaging   | Pack size   |
|------------------|-------------------|------------|--------------------------|---------------------------|-----------------------|-------------|
| EU/1/07/386/001  | Toviaz            | 4 mg       | Prolonged-release tablet | Oral use                  | blister (alu/alu)     | 7 tablets   |
| EU/1/07/386/002  | Toviaz            | 4 mg       | Prolonged-release tablet | Oral use                  | blister (alu/alu)     | 14 tablets  |
| EU/1/07/386/003  | Toviaz            | 4 mg       | Prolonged-release tablet | Oral use                  | blister (alu/alu)     | 28 tablets  |
| EU/1/07/386/004  | Toviaz            | 4 mg       | Prolonged-release tablet | Oral use                  | blister (alu/alu)     | 56 tablets  |
| EU/1/07/386/005  | Toviaz            | 4 mg       | Prolonged-release tablet | Oral use                  | blister (alu/alu)     | 98 tablets  |
| EU/1/07/386/006  | Toviaz            | 8 mg       | Prolonged-release tablet | Oral use                  | blister (alu/alu)     | 7 tablets   |
| EU/1/07/386/007  | Toviaz            | 8 mg       | Prolonged-release tablet | Oral use                  | blister (alu/alu)     | 14 tablets  |
| EU/1/07/386/008  | Toviaz            | 8 mg       | Prolonged-release tablet | Oral use                  | blister (alu/alu)     | 28 tablets  |
| EU/1/07/386/009  | Toviaz            | 8 mg       | Prolonged-release tablet | Oral use                  | blister (alu/alu)     | 56 tablets  |
| EU/1/07/386/010  | Toviaz            | 8 mg       | Prolonged-release tablet | Oral use                  | blister (alu/alu)     | 98 tablets  |
| EU/1/07/386/011  | Toviaz            | 4 mg       | Prolonged-release tablet | Oral use                  | blister (alu/alu)     | 84 tablets  |
| EU/1/07/386/012  | Toviaz            | 8 mg       | Prolonged-release tablet | Oral use                  | blister (alu/alu)     | 84 tablets  |
| EU/1/07/386/013  | Toviaz            | 4 mg       | Prolonged-release tablet | Oral use                  | bottle (HDPE)         | 30 tablets  |
| EU/1/07/386/014  | Toviaz            | 4 mg       | Prolonged-release tablet | Oral use                  | bottle (HDPE)         | 90 tablets  |
| EU/1/07/386/015  | Toviaz            | 8 mg       | Prolonged-release tablet | Oral use                  | bottle (HDPE)         | 30 tablets  |
| EU/1/07/386/016  | Toviaz            | 8 mg       | Prolonged-release tablet | Oral use                  | bottle (HDPE)         | 90 tablets  |
| EU/1/07/386/017  | Toviaz            | 4 mg       | Prolonged-release tablet | Oral use                  | blister (alu/alu)     | 100 tablets |
| EU/1/07/386/018  | Toviaz            | 8 mg       | Prolonged-release tablet | Oral use                  | blister (alu/alu)     | 100 tablets |
| EU/1/07/386/019  | Toviaz            | 4 mg       | Prolonged-release tablet | Oral use                  | blister (alu/alu)     | 30 tablets  |
| EU/1/07/386/020  | Toviaz            | 8 mg       | Prolonged-release tablet | Oral use                  | blister (alu/alu)     | 30 tablets  |